Clinical Trial: TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07489755) titled 'TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients' on March 18.

Brief Summary: A Phase III study evaluating the safety and efficacy of TGRX-678 in CML-CP patients resistant from or intolerant to at least 3 TKIs

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Chronic Myelogenous Leukemia Chronic Myelogenous Leukemia - Chronic Phase

Intervention: DRUG: TGRX-678

Patients will be given TGRX-678 for oral administration

DRUG: TKI

Patient will take TKI of investigator's choice for oral administration

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shenzhen TargetRx Co., Ltd.

Disclaimer:...